Home/Pipeline/Gene Therapy for Type 1 Diabetes

Gene Therapy for Type 1 Diabetes

Type 1 Diabetes

PreclinicalActive

Key Facts

Indication

Type 1 Diabetes

Phase

Preclinical

Status

Active

Company

Endsulin

About Endsulin

Endsulin is a private, preclinical-stage biotech founded in 2018, headquartered in San Diego, CA (with a noted research base in Madison, WI), focused on a curative gene therapy for Type 1 Diabetes. The company's core platform involves delivering a genetic factor to hepatocytes to 'switch on' insulin production, aiming to restore the body's natural glucose regulation. Led by a founder with a transplant surgery background and advised by a seasoned Scientific Advisory Board, Endsulin is pursuing a potentially transformative, one-time treatment to free patients from the lifelong burden of insulin dependency.

View full company profile

Therapeutic Areas

Type 1 Diabetes Metabolic Disease

Other Type 1 Diabetes Drugs

Drug	Company	Phase	Status
eRapa	Biodexa Pharmaceuticals	Preclinical	Research
ImmCelz™	Creative Medical Technology Holdings	Clinical Trial	Active
Adimune (ADi-001/002)	Aditxt	Preclinical / Early Clinical	Active
MSC‑Diabetes	Advancells	Phase 1	Active
BioChaperone® Lispro (THDB0206)	Adocia	Phase 3	Active
AdoShell® Islet Cell Therapy	Adocia	Preclinical	Platform Development
Pediatric Indications (<2 years)	Tandem Diabetes	Research	Exploratory
Icovamenib (BMF-219)	Biomea Fusion	Phase 2	Completed Follow-up, Data Pending
Undisclosed Novel Strategy	CG Scientific	Pre-clinical	Early Research
Sotagliflozin	Lexicon Pharmaceuticals	Phase 3	Regulatory Path Uncertain
Stem Cell-Derived Beta Cells	BioTalentum	Pre-clinical	Active
NICHE	Continuity Biosciences	Pre-clinical	Active